Searchable abstracts of presentations at key conferences in endocrinology

ea0073aep482 | Pituitary and Neuroendocrinology | ECE2021

Factors that contribute to dopamine agonist resistance of prolactinomas

Berdeli Maria , Trifanescu Raluca , Caragheorgheopol Andra , Anda Dumitraşcu , Poiana Catalina

IntroductionProlactinomas are the most common hormone-secreting pituitary tumours encountered in the clinic. They are usually treated with dopamine agonists (DA): bromocriptine (BRC) and cabergoline (CAB), which are highly effective in the majority of cases. DA resistance is the failure to achieve normal levels of prolactin and, or reduction of the adenoma with at least 50%.Aimto assess the prevalence of the ...